Disclosures: Matthew Menkart: Nothing to Disclose, James Haddad: Nothing to Disclose, Moumita Chakraborty: Nothing to Disclose, Rownock Afruza: Nothing to Disclose, Jenna Oringher: Nothing to Disclose, Gabriella Quinn: Nothing to Disclose, Elizabeth Townsend: Nothing to Disclose, Kareen Akiva: Nothing to Disclose, Lisa Scheuing: Nothing to Disclose, Rabab Ali: Nothing to Disclose, Christopher Koh: Nothing to Disclose, Regina Umarova: Nothing to Disclose, Elliott Levy: Nothing to Disclose, Etzion Ohad: Nothing to Disclose, David Kleiner: Nothing to Disclose, Theo Heller: Nothing to Disclose 549 TAILORING HCC RISK STRATIFICATION IN CHRONIC HEPATITIS C PATIENTS FOLLOWING VIRAL ERADICATION: A SIMPLE ALGORITHM UTILIZING ALPHA-FETOPROTEIN Yen-Chun Liu 1 Yu-Ting Kao 1 Ya-Ting Cheng 1 Yi-Cheng Chen 1 Yi-Chung Hsieh 1 Rachel Wen-Juei Jeng 1 Wei-Ting Chen 1 Chun-Yen Lin 1 Rong-Nan Chien 1 Dar-In Tai 1 I-Shyan Sheen 1 , 1 Chang Gung Memorial Hospital, Linkou branch Background: Guidelines recommend hepatocellular carcinoma (HCC) surveillance for chronic hepatitis C (CHC) patients with advanced liver fibrosis (ACLD) who achieve sustained virological response (SVR) due to an annual HCC incidence 1%
KEY INGREDIENTS: L-Glutathione
Ducklings were housed at a stocking density of 4.5 birds/m, and gas heaters were used to maintain the required temperature
2.4 HBA measurement Blood samples collected on the 100th and 138th days of the gestation
